Discovery of new anti TB drugs is the necessity of prime importance to control the global epidemic of Tuberculosis (TB). To ensure the sensitivity of the drug over a range of different strains of Mycobacterium tuberculosis (M.TB), new targets are required. Rosuvastatin has been studied to inhibit the key MEP pathway enzyme during in silico investigations. We have treated M.TB culture with different concentrations of rosuvastatin in vitro. We observed delay in growth of cultures with 100 µg/ml and 200 µg/ml concentration of rosuvastatin as compared with controls and cultures with lower rosuvastatin concentrations. Based on these results, we can assume that rosuvastatin has some growth retarding effects on M.TB and treatment with higher concentrations may restrict the M.TB growth.
